article · The Scientific World JOURNAL
Standard treatments for male sexual dysfunction, such as testosterone replacement therapy and phosphodiesterase Type 5 inhibitors, can be costly and lead to unwanted side effects. Researchers investigated the therapeutic effects of Tribulus cistoides extracts on male Wistar rats suffering from nicotine-induced sexual dysfunction. Nicotine administration impaired animal mating behaviours, lowered reproductive hormone concentrations, and disturbed oxidative balance. Administering aqueous and ethanol extracts of the plant over nine days effectively reversed these deficits. The botanical extracts restored mount and intromission frequencies, reduced mount latency, and significantly increased serum testosterone, gonadotropin, and nitric oxide levels back towards baseline values. In addition, the treatments improved testicular oxidative balance and reproductive tissue biochemistry. These restorative effects are attributed to bioactive compounds including saponins, flavonoids, and alkaloids, demonstrating the plant's potential as a plant-based treatment for sexual dysfunction.
Current medical treatments for sexual dysfunction can be unaffordable and cause adverse side effects. Demonstrating that a botanical extract can reverse nicotine-induced reproductive impairments and restore hormone levels in preclinical models supports the search for safer, more accessible, plant-based therapeutic options.
This work points to the early-stage development of natural aphrodisiacs or therapies for male sexual dysfunction by pharmaceutical and nutraceutical developers. Because the findings are derived exclusively from an in vivo animal model, the technology remains at an early, preclinical stage of research and requires extensive further testing before human use.
AI-generated from the published abstract. Always read the original work before citing.
Male sexual dysfunction is a common condition, typically managed with phosphodiesterase Type 5 inhibitors and testosterone replacement therapy. However, these treatments often have undesirable side effects and are expensive, prompting interest in plant‐based alternatives. This study investigated the aphrodisiac and androgenic potential of Tribulus cistoides ( T. cistoides ) in a nicotine‐induced model of sexual dysfunction in male Wistar rats. A total of 45 male rats were divided into nine groups ( n = 5 per group). Group 1 served as the normal control; Group 2 received nicotine only (1 mg/kg) to induce dysfunction; Group 3 received sildenafil citrate (5 mg/kg) as a positive control. Groups 4–6 were administered nicotine plus aqueous extracts of T. cistoides at doses of 50, 100, and 150 mg/kg, respectively. Groups 7–9 received nicotine plus ethanol extracts at the same doses. Sexual behavior was assessed on Days 1, 5, and 9, and animals were sacrificed on Day 10 for biochemical and histological analyses. Outcomes measured included reproductive organ weights, serum levels of testosterone, FSH, LH, oxidative stress markers, testicular protein content, and seminal vesicle fructose levels. Nicotine exposure impaired sexual behavior, as evidenced by increased mount latency and decreased mount frequency, intromission frequency, and penile licking. However, treatment with the plant extract effectively reversed these effects, restoring the sexual behavior parameters toward normal levels. Nicotine also significantly reduced testosterone levels (0.079 ± 0.006 ng/mL), while T. cistoides extracts markedly restored hormone levels to 1.002 ± 0.165 ng/mL (aqueous) and 0.865 ± 0.041 ng/mL (ethanol) and improved nitric oxide levels, and gonadotropin concentrations. Additionally, the extracts restored testicular oxidative balance and enhanced reproductive tissue biochemistry. These effects are likely mediated by bioactive phytochemicals such as saponins, alkaloids, and flavonoids, which may promote vasodilation, modulate hormone levels, and enhance nitric oxide production. Findings suggest that T. cistoides may offer a natural alternative for managing male sexual dysfunction with fewer side effects than conventional drugs.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1155/tswj/7410030
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
